文献速递神经免疫认知障碍与痴呆

多发性硬化中的丘脑萎缩:贯穿疾病全程的神经退行性变磁共振成像标志物

Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease.
PubMed 文献 · Ann Neurol · 2018-02-09

研究纳入601例受试者(2632次MRI扫描),其中520例复发起病型多发性硬化(MS)患者每年接受标准化3T MRI平均4.1年,81例健康对照在同一扫描仪纵向扫描。结果显示MS患者丘脑体积年下降-0.71%(95%CI -0.77%至-0.64%),健康对照为-0.28%(95%CI -0.58%至0.02%),组间差异P=0.007。丘脑萎缩在MS早期即出现且贯穿疾病全程。

要点

  • MS患者丘脑体积年下降-0.71%,健康对照-0.28%,差异有统计学意义(P=0.007)。
  • 丘脑萎缩速率在MS疾病全程及各临床亚型中保持一致。
  • 24个月研究检测最大效应量所需样本量:α=0.1时每组80例,α=0.05时每组100例。

核心结论

  • 丘脑萎缩在MS早期即出现并贯穿疾病全程,初步样本量计算显示可行,支持其作为神经退行性变相关MRI标志物的价值。

研究设计与样本

  • 研究纳入601例受试者(2632次MRI扫描),其中520例复发起病型MS患者(临床孤立综合征90例、复发缓解型MS 392例、继发进展型MS 38例)每年接受标准化3T MRI平均4.1年,包括1mm³三维T1加权序列(2485次MRI扫描);81例健康对照在同一扫描仪使用同一方案纵向扫描(147次MRI扫描)。

主要发现

  • MS患者丘脑体积年下降-0.71%(95%CI -0.77%至-0.64%),健康对照年下降-0.28%(95%CI -0.58%至0.02%),组间差异P=0.007。
  • 丘脑体积下降速率在MS疾病全程及各MS临床亚型中保持一致。
  • 24个月研究以80%把握度检测最大效应量所需样本量:α=0.1时每组80例,α=0.05时每组100例。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Thalamic volume is a candidate magnetic resonance imaging (MRI)-based marker associated with neurodegeneration to hasten development of neuroprotective treatments. Our objective is to describe the longitudinal evolution of thalamic atrophy in MS and normal aging, and to estimate sample sizes for study design. METHODS: Six hundred one subjects (2,632 MRI scans) were analyzed. Five hundred twenty subjects with relapse-onset MS (clinically isolated syndrome, n = 90; relapsing-remitting MS, n = 392; secondary progressive MS, n = 38) underwent annual standardized 3T MRI scans for an average of 4.1 years, including a 1mm3 3-dimensional T1-weighted sequence (3DT1; 2,485 MRI scans). Eighty-one healthy controls (HC) were scanned longitudinally on the same scanner using the same protocol (147 MRI scans). 3DT1s were processed using FreeSurfer's longitudinal pipeline after lesion inpainting. Rates of normalized thalamic volume loss in MS and HC were compared in linear mixed effects models. Simulation-based sample size calculations were performed incorporating the rate of atrophy in HC. RESULTS: Thalamic volume declined significantly faster in MS subjects compared to HC, with an estimated decline of -0.71% per year (95% confidence interval [CI] = -0.77% to -0.64%) in MS subjects and -0.28% per year (95% CI = -0.58% to 0.02%) in HC (p for difference = 0.007). The rate of decline was consistent throughout the MS disease duration and across MS clinical subtypes. Eighty or 100 subjects per arm (α = 0.1 or 0.05, respectively) would be needed to detect the maximal effect size with 80% power in a 24-month study. INTERPRETATION: Thalamic atrophy occurs early and consistently throughout MS. Preliminary sample size calculations appear feasible, adding to its appeal as an MRI marker associated with neurodegeneration. Ann Neurol 2018;83:223-234.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Azevedo CJ, Cen SY, Khadka S, et al. Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol. 2018. PMID: 29328531. doi:10.1002/ana.25150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。